These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31174929)

  • 21. An Ultra-Brief Mindfulness-Based Intervention for Patients in Treatment for Opioid Addiction with Buprenorphine: A Primary Care Feasibility Pilot Study.
    Bloom-Foster J; Mehl-Madrona L
    J Altern Complement Med; 2020 Jan; 26(1):34-43. PubMed ID: 31825240
    [No Abstract]   [Full Text] [Related]  

  • 22. Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
    Wenzel K; Selby V; Wildberger J; Lavorato L; Thomas J; Fishman M
    J Subst Abuse Treat; 2021 Jun; 125():108306. PubMed ID: 34016297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing access to family planning services among women receiving medications for opioid use disorder: A pilot randomized trial examining a peer-led navigation intervention.
    Rinehart DJ; Stowell M; Collings A; Durfee MJ; Thomas-Gale T; Jones HE; Binswanger I
    J Subst Abuse Treat; 2021 Jul; 126():108318. PubMed ID: 34116817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methamphetamine use and illicit opioid use during buprenorphine treatment.
    Kratina-Hathaway Z; Radick AC; Leroux BG; Blalock K; Kim TW; Darnton J; Saxon AJ; Samet JH; Tsui JI
    J Subst Use Addict Treat; 2023 Aug; 151():. PubMed ID: 37811395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD).
    Khatri UG; Lee K; Lin T; D'Orazio JL; Patel MS; Shofer FS; Perrone J
    J Med Toxicol; 2022 Jul; 18(3):205-213. PubMed ID: 35415804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study design to evaluate a group-based therapy for support persons of adults on buprenorphine/naloxone.
    Osilla KC; Becker K; Ecola L; Hurley B; Manuel JK; Ober A; Paddock SM; Watkins KE
    Addict Sci Clin Pract; 2020 Jul; 15(1):25. PubMed ID: 32653029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study.
    Schuman-Olivier Z; Fatkin T; Creedon TB; Samawi F; Moore SK; Okst K; Fredericksen AK; Oxnard AS; Roll D; Smith L; Cook BL; Weiss RD
    Am J Addict; 2023 May; 32(3):244-253. PubMed ID: 36470641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
    Peter SC; Murphy JG; Witkiewitz K; Hand SB; Thomas F; Johnson KC; Cowan R; Harris M; Derefinko KJ
    Trials; 2023 Mar; 24(1):237. PubMed ID: 36991453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychological and Autonomic Correlates of Emotion Dysregulation among Women in Substance Use Disorder Treatment.
    Price CJ; Crowell SE; Pike KC; Cheng SC; Puzia M; Thompson EA
    Subst Use Misuse; 2019; 54(1):110-119. PubMed ID: 30273086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
    Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
    Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study assessing acceptability and feasibility of hatha yoga for chronic pain in people receiving opioid agonist therapy for opioid use disorder.
    Uebelacker LA; Van Noppen D; Tremont G; Bailey G; Abrantes A; Stein M
    J Subst Abuse Treat; 2019 Oct; 105():19-27. PubMed ID: 31443887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial.
    Garland EL; Hanley AW; Kline A; Cooperman NA
    Drug Alcohol Depend; 2019 Oct; 203():61-65. PubMed ID: 31404850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
    Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
    Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
    Tsui JI; Leroux BG; Radick AC; Schramm ZA; Blalock K; Labelle C; Heerema M; Klein JW; Merrill JO; Saxon AJ; Samet JH; Kim TW
    Drug Alcohol Depend; 2021 Oct; 227():108917. PubMed ID: 34399136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study.
    Langlois J; Nolan S; Dickhout P; Cui Z; Paterson J; Fairbairn N; Socías ME
    Subst Use Addctn J; 2024 Apr; 45(2):176-180. PubMed ID: 38254287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telehealth Mindfulness-Oriented Recovery Enhancement vs Usual Care in Individuals With Opioid Use Disorder and Pain: A Randomized Clinical Trial.
    Cooperman NA; Lu SE; Hanley AW; Puvananayagam T; Dooley-Budsock P; Kline A; Garland EL
    JAMA Psychiatry; 2024 Apr; 81(4):338-346. PubMed ID: 38061786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.